As part of the COVID-19 National Response Team's effort to combat COVID-19, the Department of Defense has created this industry portal as a one-stop shop for defense industry, commercial companies and academia to share creative ideas with federal agencies to combat the virus.

All resources and solutions are welcome from industry, academia, venture capital firms, individual contributors and more. Start by using the Request for Information (RFI) form below to share your capability with the team and explore additional resources further down the page.

The COVID-19 Telehealth Program will provide $200 million in funding, appropriated by Congress as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help health care providers provide connected care services to patients at their homes or mobile locations in response to the novel Coronavirus 2019 disease (COVID-19) pandemic.  The Program will provide immediate support to eligible health care providers responding to the COVID-19 pandemic by fully funding

HDI will select up to ten projects through the call for proposals and its current portfolio of drugs in development. Awarded projects will run for 12 months, with the possibility of extending the engagement. Read full press release announcing the call for proposals.

Award recipients will receive:

COVID-19 has had medical, financial, and social impacts on our Arizona communities. These impacts have been uneven at best. For some community members, the consequences of isolation has been devastating. Recovery may be even more uneven and, in some ways, more complicated. To support researchers at UArizona to respond to questions related to the consequences and responses related to COVID-19 in our communities, the Drachman Institute will fund up to $10,000 in seed grants for 1 to 3 projects meeting the following criteria:

Our work to improve diagnostic performance will focus on three clinical categories – acute vascular events, infections and cancers. As we embark on this work, our primary strategy is to strengthen accountability for diagnostic excellence by helping to develop and validate new measures for diagnostic performance. In addition, we will look at opportunities to support growth and capacity of the field – preparing leaders dedicated to working on the issue of diagnostic excellence.

This program area priority addresses the need to develop and deploy rapid, reliable, and readily adoptable strategies across the food and agriculture enterprise in response to COVID-19. These strategies should mitigate urgent threats from the COVID-19 virus and ensure the availability of an accessible, safe, nutritious, and abundant food supply. Proposals may be local, regional, or national in scope and should employ interdisciplinary teams with the capacity to address the range of problems faced by the entire food and agriculture enterprise, from production to consumption.

NIGMS will accept applications for Competitive Revisions to active U24 awards for eligible organizations to rapidly provide pilot or supplementary funds to researchers studying the development of predictive models for the spread of SARS-CoV-2 and outcomes of possible COVID-19 public health intervention measures in order to accelerate such research.

Eligible organizations are those with an active NIGMS U24 award responsible for storing, managing, and promoting the shared efforts of a network of researchers studying the modeling of infectious diseases.

The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics.